Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026
Seer, Inc. showcases its Proteograph Product Suite and AI-driven multi-cancer screening technology at the 2026 ASMS Annual Conference, highlighting breakthroughs in scalable proteomics and data processing infrastructure. Collaborations include large-scale plasma proteomics studies for precision medicine and advancements in biomarker discovery, unde…